Prescient Therapeutics Limited (ASX:PTX)

Market Cap	67.30M +70.5%
Revenue (ttm)	4.36M +17.3%
Net Income	-7.32M
EPS	-0.01
Shares Out	1.05B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	813,681
Average Volume	1,452,544
Open	0.0640
Previous Close	0.0640
Day's Range	0.0640 - 0.0670
52-Week Range	0.0380 - 0.1250
Beta	0.22
RSI	43.23
Earnings Date	Feb 26, 2026

About Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PTX

Financial Performance

In fiscal year 2025, Prescient Therapeutics's revenue was 4.36 million, an increase of 17.35% compared to the previous year's 3.71 million. Losses were -7.32 million, -11.11% less than in 2024.